GlassScriptPhysician profile
Mardelle Delight
NPI 1255422598
$5,082.46
in general payments reported to CMS, 2019-2025
24 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $201 · 2021: $249 · 2022: $395 · 2023: $1,271 · 2024: $1,296 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,562 · Education: $85.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,561.65 |
| Education | $85.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.03 | 2021-2025 | Vraylar, Qulipta, Synthroid |
| Novo Nordisk INC | $745.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $547.86 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $513.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $370.88 | 2019-2024 | Fasenra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $307.41 | 2020-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Amgen INC. | $282.08 | 2019-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $249.57 | 2019-2024 | Xarelto |
| Pfizer INC. | $215.25 | 2020-2025 | |
| Dexcom, INC. | $166.30 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $159.05 | 2019-2021 | |
| Astellas Pharma US INC | $157.49 | 2023-2025 | Veozah |
| Cvrx, INC. | $107.50 | 2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $62.95 | 2019-2020 | |
| Exact Sciences Corporation | $59.23 | 2023-2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.57 | 2019-2020 | |
| Boston Scientific Corporation | $53.76 | 2025 | Intracept, Watchman Flx |
| Radius Health, INC. | $50.41 | 2025 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.41 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $19.72 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $18.54 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $17.49 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.98 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mardelle Delight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.